Crispr Pioneer Launches Startup to Make Tailored Gene-Editing Treatments
Revolutionizing Gene-Editing: Aurora Therapeutics Aims to Scale Personalized Treatments for Rare Diseases
In a groundbreaking move, gene-editing pioneer Jennifer Doudna has co-founded a new startup called Aurora Therapeutics, which aims to scale personalized gene-editing treatments for rare diseases. Doudna, one of the inventors of the gene-editing system known as Crispr, won a Nobel Prize in 2020 for her work on the technology. Aurora plans to take advantage of a new regulatory pathway announced by the Food and Drug Administration (FDA) officials Marty Makary and Vinay Prasad, which allows for the approval of personalized treatments for rare and fatal diseases based on data from just a handful of patients.
The FDA's "Plausible Mechanism Pathway"
The new FDA pathway, called the "plausible mechanism pathway," provides a way for rare disease treatments to be approved when a large, randomized trial isn't possible. Typically, new drugs must be tested in hundreds, if not thousands, of patients in order to get regulatory approval. However, for drug trials of rare diseases, it's difficult to recruit that many patients because so few people have the disease. The new FDA pathway allows manufacturers to demonstrate success with several consecutive patients with different bespoke therapies, and then move toward granting marketing authorization for the product.
Aurora's Strategy: Swapping Out Guide RNA
Aurora's strategy involves swapping out the guide RNA to make several versions of a PKU therapy that address different mutations. Previously, the FDA would have considered every version a totally new drug, each requiring its own clinical trial. But now, Aurora will be able to use the same technology platform to treat many mutations that cause PKU with less regulatory red tape. The company will use base editing, a more precise form of Crispr, and will have a standardized process to streamline the design and manufacturing of its therapies.
The Power of Bespoke Gene-Editing
Aurora's approach is based on the concept of bespoke gene-editing, where a personalized treatment is designed for each patient based on their unique genetic profile. This approach has already shown promise in treating rare diseases, including the case of baby KJ, who received a gene-editing treatment made just for him. The treatment, designed by scientists at the Innovative Genomics Institute, was able to correct a rare genetic mutation that was causing toxic ammonia to build up in his small body.
The Future of Crispr: Turning a Corner
While Crispr has yet to live up to its transformative potential, several Crispr companies have downsized, and others have shut down in recent years. However, experts believe that the field is turning a corner as the technology matures. "We are finally at a place where Crispr on demand has had all the technical problems worked out," says Fyodor Urnov, Aurora's cofounder and a genome editing scientist at UC Berkeley. "I can say with reasonable certainty that, three to four years from now, there will be other children with their personalized editors."
Implications and Practical Insights
The implications of Aurora's approach are significant, as it has the potential to revolutionize the treatment of rare diseases. By using bespoke gene-editing, patients can receive personalized treatments that are tailored to their unique genetic profiles. This approach has the potential to improve treatment outcomes, reduce side effects, and increase patient satisfaction. Additionally, the use of base editing and a standardized process for designing and manufacturing therapies has the potential to streamline the development of new treatments and reduce regulatory red tape.
Conclusion
Aurora Therapeutics is a groundbreaking startup that aims to scale personalized gene-editing treatments for rare diseases. By taking advantage of the FDA's "plausible mechanism pathway," the company plans to use bespoke gene-editing to treat many mutations that cause PKU with less regulatory red tape. The implications of this approach are significant, as it has the potential to revolutionize the treatment of rare diseases and improve patient outcomes. As the field of Crispr continues to mature, it is likely that we will see more companies like Aurora Therapeutics emerge, bringing new and innovative treatments to patients in need.
